Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 131.87 USD -0.04% Market Closed
Market Cap: 14B USD

Relative Value

The Relative Value of one ITCI stock under the Base Case scenario is hidden USD. Compared to the current market price of 131.87 USD, Intra-Cellular Therapies Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ITCI Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
39
vs Industry
8
Median 3Y
16.7
Median 5Y
20.6
Industry
2.6
Forward
14.5
vs History
vs Industry
Median 3Y
-85.1
Median 5Y
-29.1
Industry
21.4
Forward
658.9
vs History
vs Industry
Median 3Y
-117.9
Median 5Y
-28.3
Industry
16.4
vs History
vs Industry
Median 3Y
-117.3
Median 5Y
-28.3
Industry
22.8
vs History
0
vs Industry
5
Median 3Y
10.1
Median 5Y
8
Industry
2.2
vs History
39
vs Industry
8
Median 3Y
15.2
Median 5Y
19.1
Industry
2.9
Forward
13.5
vs History
39
vs Industry
10
Median 3Y
16.4
Median 5Y
20.9
Industry
5.5
vs History
vs Industry
Median 3Y
-55
Median 5Y
-24.5
Industry
13
Forward
448.2
vs History
vs Industry
Median 3Y
-54.8
Median 5Y
-24.5
Industry
16.5
Forward
-1 119.5
vs History
vs Industry
Median 3Y
-101.1
Median 5Y
-25.6
Industry
15.6
vs History
vs Industry
Median 3Y
-100.6
Median 5Y
-25.6
Industry
18.7
vs History
25
vs Industry
3
Median 3Y
28.9
Median 5Y
35
Industry
1.9

Multiples Across Competitors

ITCI Competitors Multiples
Intra-Cellular Therapies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
14B USD 20.6 -187.6 -111.9 -111.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.3 158.6
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average P/E: 24.3
Negative Multiple: -187.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average EV/EBITDA: 439.7
Negative Multiple: -111.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average EV/EBIT: 1 883.3
Negative Multiple: -111.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5